AKT1 and acute myeloid leukemia: This perspective is particularly intriguing in that STAT3 has been demonstrated to regulate leukemia stem cell but not hematopoietic stem cell survival [52]; thus, drugs that target simultaneously STAT3, AKT and NF-κB in AML could produce the effect of eradicating the malignant, but not the normal, stem cell pool.